In 2018, the efficacy of nivolumab in combination with ipilimumab, an ICI targeting CTLA4, was first demonstrated in a phase I trial (CheckMate 012) as a first-line treatment of advanced NSCLC [219]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.